Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNP | P00491 | 4/20 | 0.51 |
| ▸ | TYMS | P04818 | 6/20 | 0.43 |
| ▸ | DHFR | P00374 | 2/20 | 0.42 |
| ▸ | FOLR2 | P14207 | 1/20 | 0.41 |
| ▸ | FOLR1 | P15328 | 1/20 | 0.41 |
| ▸ | GART | P22102 | 1/20 | 0.41 |
| ▸ | ATIC | P31939 | 1/20 | 0.41 |
| ▸ | SHMT1 | P34896 | 1/20 | 0.41 |
| ▸ | SLC19A1 | P41440 | 1/20 | 0.41 |
| ▸ | FRK | P42685 | 1/20 | 0.41 |
| ▸ | SLC46A1 | Q96NT5 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19929240 | 1.00 | PNP (0.51) | PNPTYMSDHFRFOLR2FOLR1 | |
| SCHEMBL19929106 | 1.00 | PNP (0.51) | PNPTYMSDHFRFOLR2FOLR1 | |
| SCHEMBL21187099 | 0.89 | TYMS (0.46) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL19929242 | 0.79 | TYMS (0.51) | PNPTYMSDHFRFOLR2FOLR1 | |
| SCHEMBL19929245 | 0.77 | PNP (0.48) | PNPTYMS | |
| SCHEMBL19929241 | 0.76 | PNP (0.48) | PNPTYMS | |
| SCHEMBL21067593 | 0.76 | TYMS (0.55) | TYMSDHFRFOLR2FOLR1GART | |
| SCHEMBL25393619 | 0.75 | TYMS (0.46) | PNPTYMSDHFRFOLR2FOLR1 | |
| SCHEMBL24231496 | 0.75 | TYMS (0.46) | PNPTYMSDHFRFOLR2FOLR1 | |
| SCHEMBL25395640 | 0.75 | TYMS (0.46) | PNPTYMSDHFRFOLR2FOLR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2023-06-27 | — | — | US | disclosed |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2023-06-27 | — | — | US | disclosed |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2023-06-27 | — | — | US | disclosed |
| CN-110035758-B | Compounds for the treatment of diseases associated with mitochondrial dysfunction | AMA生物制药公司 | 2023-06-16 | — | — | CN | disclosed |
| US-20230040247-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | AMABIOTICS (FR) | 2023-02-09 | — | — | US | disclosed |
| WO-2021048430-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | AMABIOTICS (FR) | 2021-03-18 | — | — | WO | disclosed |
| WO-2021048431-A1 | COMPOUNDS FOR TREATING ATAXIA | AMABIOTICS (FR) | 2021-03-18 | — | — | WO | disclosed |
| US-20210052589-A1 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | AMABIOTICS (FR) | 2021-02-25 | — | — | US | disclosed |
| US-20210046056-A1 | Compounds for Treating Diseases Associated with a Mitochondrial Dysfunction | AMABIOTICS (FR) | 2021-02-18 | — | — | US | disclosed |
| US-20210046056-A1 | Compounds for Treating Diseases Associated with a Mitochondrial Dysfunction | AMABIOTICS (FR) | 2021-02-18 | — | — | US | disclosed |
| US-10857135-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2020-12-08 | — | — | US | disclosed |
| US-10857135-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | AMABIOTICS (FR) | 2020-12-08 | — | — | US | disclosed |
| WO-2019170834-A1 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | AMABIOTICS (FR) | 2019-09-12 | — | — | WO | disclosed |
| US-20190224174-A1 | COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFUNCTION | AMABIOTICS (FR) | 2019-07-25 | — | — | US | disclosed |
| US-20190224174-A1 | COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFUNCTION | AMABIOTICS (FR) | 2019-07-25 | — | — | US | disclosed |
| WO-2018041919-A1 | COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFONCTION | AMABIOTICS (FR) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230040247-A1 | COMPOUNDS FOR TREATING NEURODEGENERATIVE DISEASES | SNCA, HTT, PARK7 | PNP 3067/4885TYMS 4634/4885DHFR 2566/4885 |
| US-20210046056-A1 | Compounds for Treating Diseases Associated with a Mitochondrial Dysfunction | NDUFAB1, FH, TFAM | PNP 2691/4885TYMS 3412/4885DHFR 937/4885 |
| US-20190224174-A1 | COMPOUNDS FOR TREATING DISEASES ASSOCIATED WITH A MITOCHONDRIAL DYSFUNCTION | NDUFAB1, FH, TFAM | PNP 2691/4885TYMS 3412/4885DHFR 937/4885 |
| US-10857135-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | NDUFAB1, FH, TFAM | PNP 2691/4885TYMS 3412/4885DHFR 937/4885 |
| US-20210052589-A1 | COMPOUNDS FOR TREATING ALZHEIMER'S DISEASE | PSEN1, PSEN2, MAPT | PNP 3884/4885TYMS 3657/4885DHFR 685/4885 |
| US-11684611-B2 | Compounds for treating diseases associated with a mitochondrial dysfunction | NDUFAB1, FH, TFAM | PNP 2691/4885TYMS 3412/4885DHFR 937/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.